Examples for molecular changes associated with the development of resistance are, for instance, the apparition of the EGFR T790M resistance mutation in NSCLC (152), c-MET mutations and loss of anti-VEGF agent effectiveness (153), or therapy resistance mediated by lncRNA inhibition (154), and surely the further is known about the biological features of extensive tumor datasets the more clues we will have to the molecular changes underpinning drug response and resistance. Here, EGFR is linked to non-small cell lung carcinoma.